Bio-Techne Corporation (NASDAQ:TECH) has been making strategic moves recently both on and off the market. It encountered a number of setbacks in Q1 but its intrinsic value estimate indicates its shares could be 32% above their current rate. Investors appear confident in the biotech company, as demonstrated by both Tower Research Capital LLC TRC and TD Asset Management Inc acquiring substantial shares. Important corporate developments include the appointment of Matthew F. McManus as President and CEO Kim Kelderman, expansion of the board of directors, and a patent infringement lawsuit against Molecular Instruments. Furthermore, the collaboration announcement with Nikon Instruments and a new distribution agreement with Thermo Fisher Scientific indicates a focus on partnership development. Bio-Techne is also gaining recognition through awards such as ELISA Kit Supplier of the Year and Spatial Biology Innovation from CiteAb. The company faced mixed results during Q2 and Q3 but remains committed to presenting at several investor conferences. It has declared a dividend and is expected to present at the upcoming LEERINK Partners Healthcare Crossroads Conference.
Bio-Techne Corp TECH News Analytics from Wed, 03 Mar 2021 08:00:00 GMT to Sun, 09 Jun 2024 14:31:52 GMT -
Rating 4
- Innovation 8
- Information 7
- Rumor -2
